Structural modulation of the gut microbiota and the relationship with body weight: Compared evaluation of liraglutide and saxagliptin treatment

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wang, Lin ^a   Li, Peicheng ^a   Tang, Zhaosheng ^a   Yan, Xinfeng ^a   Feng, Bo ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; ANTIDIABETIC AGENT; BACTERIAL DNA; DIPEPTIDE; GLP1R PROTEIN, MOUSE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; RNA 16S; SAXAGLIPTIN; STREPTOZOCIN;

AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BODY WEIGHT; C57BL MOUSE; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECT; EATING; EXPERIMENTAL DIABETES MELLITUS; FECES; GENE EXPRESSION; GENETICS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INTESTINE FLORA; KNOCKOUT MOUSE; MALE; METABOLISM; MICROBIOLOGY; MOUSE;

ADAMANTANE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDES; DNA, BACTERIAL; EATING; FECES; GASTROINTESTINAL MICROBIOME; GENE EXPRESSION; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RNA, RIBOSOMAL, 16S; STREPTOZOCIN;

EID: 84988369638     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep33251     Document Type: Article

References (38)

1. Drucker, D. J., Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 368, 1696-1705 (2006).
2. Vilsbøll, T., Christensen, M., Junker, A. E., Knop, F. K., Gluud, L. L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 344, d7771 (2012).
3. Astrup, A. et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 374, 1606-1616 (2009).
4. Blonde, L., Montanya, E. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. Diabetes Obes Metab. 14, 20-32 (2012).
5. Baggio, L. L., Drucker, D. J. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J. Clin Invest. 124, 4223-4226 (2014).
6. Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 444, 1027-1031 (2006).
7. Fei, N., Zhao, L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. ISME J. 7, 880-884 (2013).
8. Tolhurst, G. et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 61, 364-371 (2012).
9. Ridge regression in The elements of statistical learning: Data mining, inference, prediction 2nd edn (eds Hastic, T., Tibshirni, R., Friedman, J. ) Ch. 3, 61-68 (Springer, 2009).
10. Cai, L., Wu, H., Li, D., Zhou, K., Zou, F. Type 2 Diabetes Biomarkers of Human Gut Microbiota Selected via Iterative Sure Independent Screening Method. PLoS One. 10, e0140827 (2015).
11. Ley, R. E., Turnbaugh, P. J., Klein, S., Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. Nature. 444, 1022-1023 (2006).
12. Ley, R. E. et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 102, 11070-11075 (2005).
13. Schwiertz, A. et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 18, 190-195 (2012).
14. Arumugam, M. et al. Enterotypes of the human gut microbiome. Nature. 473, 174-180 (2011).
15. Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 500, 541-546 (2013).
16. Ivanov, I. I. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 139, 485-498 (2009).
17. Snel, J. et al. Comparison of 16S rRNA sequences of segmented filamentous bacteria isolated from mice, rats, chickens and proposal of "Candidatus Arthromitus". Int J Syst Bacteriol. 45, 780-782 (1995).
18. Kverka, M. et al. Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition. Clin Exp Immunol. 163, 250-259 (2011).
19. Wichmann, A. et al. Microbial modulation of energy availability in the colon regulates intestinal transit. Cell Host Microbe. 14, 582-590 (2013).
20. Duncan, S. H., Hold, G. L., Barcenilla, A., Stewart, C. S., Flint, H. J. Roseburia intestinalis sp. nov., a novel saccharolytic, butyrateproducing bacterium from human faeces. Int J Syst Evol Microbiol. 52, 1615-1620 (2002).
21. Rey, F. E. et al. Dissecting the in vivo metabolic potential of two human gut acetogens. J. Biol Chem. 285, 22082-22090 (2010).
22. Tilg, H., Moschen, A. R. Microbiota and diabetes: an evolving relationship. Gut. 63, 1513-1521 (2014).
23. Million, M. et al. Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog. 53, 100-108 (2012).
24. Tap, J. et al. Gut microbiota richness promotes its stability upon increased dietary fibre intake in healthy adults. Environ Microbiol. 17, 4954-4964 (2015).
25. Goodrich, J. K. et al. Human genetics shape the gut microbiome. Cell. 159, 789-799 (2014).
26. Degn, K. B. et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha-and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 53, 1187-1194 (2004).
27. Herman, G. A. et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J. Clin Endocrinol Metab. 91, 4612-4619 (2006).
28. Zhang, C. et al. Structural modulation of gut microbiota in life-long calorie-restricted mice. Nat Commun. 4, 2163 (2013).
29. Cani, P. D. et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 57, 1470-1481 (2008).
30. Schumann, R. R. et al. Structure and function of lipopolysaccharide binding protein. Science. 249, 1429-1431 (1990).
31. Edgar, R. C. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 10, 996-998 (2013).
32. Schloss, P. D. et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 75, 7537-7541 (2009).
33. Gregory, R. Warnes. et al. gplots: Various R Programming Tools for Plotting Data. Available at: https://cran. r-project. org/web/packages/gplots/. (Accessed: 28th November 2015) (2015).
34. Lozupone, C., Knight, R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 71, 8228-8235 (2005).
35. White, J. R., Nagarajan, N., Pop, M. Statistical methods for detecting differentially abundant features in clinical metagenomic samples. PLoS Comput Biol. 5, e1000352 (2009).
36. Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60 (2011).
37. Storey, J. D., Tibshirani, R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100, 9440-9445 (2003).
38. John, D. S.,rew, J. B., Alan, D., David, R. qvalue: Q-value estimation for false discovery rate control Available at: https://github. com/jdstorey/qvalue. (Accessed: 11th March 2016). (2015).